Effect of low dose vitamin K2 (MK-4) supplementation on bio-indices in postmenopausal Japanese women.
It has been reported that treatment with a pharmacological dose (45 mg/d) of menaquinone-4 (MK-4) prevents bone loss in postmenopausal women. However, it is not known whether supplementation with low dose MK-4 has beneficial effects on bone metabolism in healthy women. The aim of this study is to examine the effects of the supplementation of 1.5 mg/d MK-4 for 4 wk on bone and lipid metabolism in healthy postmenopausal Japanese women. The study was performed as a randomized double blind placebo-controlled trial. The participants aged 53-65 y were randomly assigned to 2 groups and supplemented with 1.5 mg/d of MK-4 or a placebo for 4 wk (n=20 for each group). The most marked effects of MK-4 intake were observed on serum osteocalcin (OC) concentrations. Serum undercarboxylated OC (ucOC) concentration decreased, and the gamma-carboxylated OC (GlaOC) and GlaOC/GlaOC+ucOC ratio that indicates the degree of OC gamma-carboxylation increased significantly at 2 and 4 wk compared with that at baseline in the MK-4 group. The serum ucOC and GlaOC concentrations in the MK-4 group were significantly different from those in the placebo group at 2 wk. These results suggest that supplementation with 1.5 mg/d MK-4 accelerated the degree of OC gamma-carboxylation. The concentrations of serum lipids and other indices were not different between the groups at either intervention period. Thus, the additional intake of MK-4 might be beneficial in the maintenance of bone health in postmenopausal Japanese women.
Koitaya
Noriko
N
Nutritional Epidemiology Program, National Institute of Health and Nutrition, 1-23-1, Toyama, Shinjyuku-ku, Tokyo 162-8636, Japan.
Ezaki
Junko
J
Nishimuta
Mamoru
M
Yamauchi
Jun
J
Hashizume
Erika
E
Morishita
Koji
K
Miyachi
Motohiko
M
Sasaki
Satoshi
S
Ishimi
Yoshiko
Y
D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D019587:Dietary Supplements; D004311:Double-Blind Method; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D007564:Japan; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood*; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000188:drug therapy*; D017698:Postmenopause / Q000097:blood; D014807:Vitamin D / Q000031:analogs & derivatives / Q000097:blood; D010837:Vitamin K 1 / Q000097:blood; D024482:Vitamin K 2 / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D014815:Vitamins / Q000097:blood / Q000627:therapeutic use*
D015415:Biomarkers; D008055:Lipids; D014815:Vitamins; D015675:Osteocalcin; D024482:Vitamin K 2; D014807:Vitamin D; D004958:Estradiol; D010837:Vitamin K 1; C104450:25-hydroxyvitamin D